<DOC>
	<DOC>NCT01502124</DOC>
	<brief_summary>This trial is conducted in the United States of America (USA). The aim of this trial is to evaluate the safety profiles of Norditropin® (lyophilized somatropin) and Norditropin® cartridges (liquid somatropin) in children with growth hormone deficiency.</brief_summary>
	<brief_title>Safety and Efficacy of Somatropin in Children With Growth Hormone Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism, Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Diagnosis of short stature (height maximum 2 standard deviations of mean for age and gender) or inadequate growth deemed secondary to growth hormone deficiency (GHD) Naïve to growth hormone therapy Known or suspected allergy to the trial product or related products Growth retardation attributable to causes other than GHD. Growth retardation attributable to diabetes mellitus, inborn errors of metabolism, primary bone disease, chromosomal disorders or disease of the genitourinary, cardiopulmonary, gastrointestinal or central nervous system; bone marrow transplantation or any syndrome known to give short stature (examples are: PraderWilli Syndrome, RussellSilver Syndrome, Turner Syndrome, Noonan Syndrome) Intrauterine growth retardation: birth weight below 3rd percentile, adjusted for gestational age Pregnancy or the intention to become pregnant Breastfeeding Administration of other growthaltering medication</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>